SOHO 2023 Annual Meeting-Hybrid
Sep 6-9, 2023

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.

Content to be used in accordance with local CPO guidelines

List of Presentations

ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma

Nathan Fowler

  • Presentation # CT-564 – Poster
    Sep 06, 2023 | 06:00 PM - 07:00 PM CT

This presentation will be available once the congress embargo lifts

Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Nirav Shah

  • Presentation # CT-526 – Poster
    Sep 06, 2023 | 06:00 PM - 07:00 PM CT

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound